114 related articles for article (PubMed ID: 36567192)
1. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.
Sato S; Nakamura Y; Oki E; Yoshino T
Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192
[TBL] [Abstract][Full Text] [Related]
2. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
[TBL] [Abstract][Full Text] [Related]
3. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
[TBL] [Abstract][Full Text] [Related]
4. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
5. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
[TBL] [Abstract][Full Text] [Related]
6. Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials.
Conca V; Ciracì P; Boccaccio C; Minelli A; Antoniotti C; Cremolini C
Cancer Treat Rev; 2024 May; 126():102735. PubMed ID: 38613871
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z
JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099
[TBL] [Abstract][Full Text] [Related]
8. Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
Medford AJ; Moy B; Spring LM; Hurvitz SA; Turner NC; Bardia A
Clin Cancer Res; 2023 Nov; 29(22):4540-4548. PubMed ID: 37477704
[TBL] [Abstract][Full Text] [Related]
9. ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC).
Masfarré L; Vidal J; Fernández-Rodríguez C; Montagut C
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201274
[TBL] [Abstract][Full Text] [Related]
10. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano T; Takao S; Dairaku K; Uno N; Low SA; Hashimoto M; Tsuda Y; Hisamatsu Y; Toshima T; Yonemura Y; Masuda T; Eto K; Ikegami T; Fukunaga Y; Niida A; Nagayama S; Mimori K
Cancer Sci; 2024 Jun; 115(6):1989-2001. PubMed ID: 38531808
[TBL] [Abstract][Full Text] [Related]
11. Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study.
Slater S; Bryant A; Aresu M; Begum R; Chen HC; Peckitt C; Lazaro-Alcausi R; Carter P; Anandappa G; Khakoo S; Melcher L; Potter V; Marti Marti F; Huang J; Branagan G; George N; Abulafi M; Duff S; Raja A; Gupta A; West N; Bucheit L; Rich T; Chau I; Cunningham D; Starling N
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38864835
[TBL] [Abstract][Full Text] [Related]
12. The utilization of circulating tumor DNA to predict the risk and location of relapse after curative-intent local therapy in oligometastatic colorectal cancer.
Radomski SN; Ali S; Lafaro KJ; Shubert C; Hidalgo M; Chung H; Christenson ES
J Gastrointest Surg; 2024 Apr; 28(4):534-537. PubMed ID: 38583907
[No Abstract] [Full Text] [Related]
13. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.
Verschoor N; Bos MK; Oomen-de Hoop E; Martens JWM; Sleijfer S; Jager A; Beije N
Eur J Cancer; 2024 Jun; 207():114159. PubMed ID: 38878446
[TBL] [Abstract][Full Text] [Related]
14. Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer.
Gottschalk Z; Cohen SA
Curr Oncol Rep; 2024 Jun; ():. PubMed ID: 38842605
[TBL] [Abstract][Full Text] [Related]
15. A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers.
Allan Z; Liu DS; Lee MM; Tie J; Clemons NJ
Clin Chem; 2024 Jan; 70(1):49-59. PubMed ID: 38175583
[TBL] [Abstract][Full Text] [Related]
16. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D; Oki E; Nakamura Y; Yukami H; Mishima S; Bando H; Shirasu H; Yamazaki K; Watanabe J; Kotaka M; Hirata K; Akazawa N; Kataoka K; Sharma S; Aushev VN; Aleshin A; Misumi T; Taniguchi H; Takemasa I; Kato T; Mori M; Yoshino T
Nat Med; 2023 Jan; 29(1):127-134. PubMed ID: 36646802
[TBL] [Abstract][Full Text] [Related]
17. Practical recommendations for using ctDNA in clinical decision making.
Cohen SA; Liu MC; Aleshin A
Nature; 2023 Jul; 619(7969):259-268. PubMed ID: 37438589
[TBL] [Abstract][Full Text] [Related]
18. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA.
Semenkovich NP; Szymanski JJ; Earland N; Chauhan PS; Pellini B; Chaudhuri AA
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349125
[TBL] [Abstract][Full Text] [Related]
19. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
